BioReliance (Merck) vs Pharmaron: CDMO Comparison

How does BioReliance (Merck) compare to Pharmaron?

As of Nov 2026, BioReliance (Merck): 6 FDA inspections (including 2 NAI, 4 VAI and 0 OAI), 10 EMA/MHRA GMP certificates. Signal Score 80.3. Pharmaron: 5 FDA inspections (including 4 NAI, 1 VAI and 0 OAI), 1 EMA/MHRA GMP certificate. Signal Score 86.9. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.

Side-by-side comparison of BioReliance (Merck) and Pharmaron on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Glasgow, UK · Rockville, MD
Signal Score
80/100
Quality (FDA + GMP)
97/100
FDA inspections
6
— NAI / VAI / OAI
2 / 4 / 0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
10
Clinical programs (matched)
0
Capacity
—
Modalities
AAV, Lentiviral, Biologics
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
Signal Score
87/100
Quality (FDA + GMP)
100/100
FDA inspections
5
— NAI / VAI / OAI
4 / 1 / 0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
1
Clinical programs (matched)
0
Capacity
Available
Modalities
AAV, Lentiviral, Plasmid, mAb, Antibody, Recombinant Protein, Biosimilars

Key differences

  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • BioReliance (Merck) has stronger MHRA / UK coverage (10 compliant certificates vs 1).

Across the cross-modality scorecard, Pharmaron carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.

Frequently asked: BioReliance (Merck) vs Pharmaron

How does BioReliance (Merck) compare to Pharmaron?

On CDMO Signal's composite Signal Score, BioReliance (Merck) is 80/100 and Pharmaron is 87/100; BioReliance (Merck) has 6 FDA inspections on record vs 5 for Pharmaron; European coverage is 10 active EMA+MHRA certificates for BioReliance (Merck) vs 1 for Pharmaron. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.

Which has the stronger FDA inspection record, BioReliance (Merck) or Pharmaron?

Both BioReliance (Merck) and Pharmaron maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. BioReliance (Merck) has 6 FDA inspections on record; Pharmaron has 5.

How do BioReliance (Merck) and Pharmaron compare on European GMP coverage?

BioReliance (Merck) holds 0 active EMA GMP certificates and 10 MHRA / UK certificates. Pharmaron holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

What does the Signal Score gap mean in practice?

BioReliance (Merck) carries a Signal Score of 80/100 and Pharmaron carries 87/100 — a small lead for Pharmaron. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating BioReliance (Merck) and Pharmaron for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.